Has the U.K. Market valuation changed over the past few years?

Investors are relatively neutral on the British market at the moment, indicating that they expect earnings will grow in line with historical growth rates. The market is trading close to its 3-year average PE ratio of 17.6x.

Which sectors have driven the changes within the U.K. Market?

Investors favour the Tech sector the most for future growth, which is trading close to its 3-year average PE ratio of 52.1x. The market's confidence is likely because analysts are expecting annual earnings growth of 17.0%, which is higher than its past year's earnings growth of 7.6% per year. The Financials sector is the least preferred by investors for future growth. Although, investor sentiment seems to have improved given that it's trading above its 3-year average of 10.1x.

U.K. (FTSE) Market Analysis & Valuation

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Wed, 17 Jun 2026	UK£3.0t	UK£2.0t	UK£164.6b	16x	18x	1.5x
Fri, 15 May 2026	UK£2.9t	UK£2.0t	UK£164.8b	15.9x	17.9x	1.5x
Sun, 12 Apr 2026	UK£3.0t	UK£2.0t	UK£157.3b	15.7x	19x	1.5x
Tue, 10 Mar 2026	UK£2.9t	UK£2.0t	UK£153.8b	15.9x	18.8x	1.5x
Thu, 05 Feb 2026	UK£3.0t	UK£1.9t	UK£137.9b	17.1x	21.6x	1.5x
Sat, 03 Jan 2026	UK£2.8t	UK£2.0t	UK£138.0b	16.3x	20.6x	1.5x
Mon, 01 Dec 2025	UK£2.8t	UK£2.0t	UK£139.6b	16.3x	20x	1.4x
Wed, 29 Oct 2025	UK£2.8t	UK£2.0t	UK£135.9b	16.5x	20.5x	1.4x
Fri, 26 Sep 2025	UK£2.7t	UK£2.0t	UK£136.3b	16.5x	19.5x	1.4x
Sun, 24 Aug 2025	UK£2.7t	UK£1.9t	UK£134.1b	16.1x	20.1x	1.4x
Tue, 22 Jul 2025	UK£2.5t	UK£1.9t	UK£127.1b	16.1x	19.9x	1.3x
Thu, 19 Jun 2025	UK£2.5t	UK£1.9t	UK£127.8b	16.4x	19.6x	1.3x
Sat, 17 May 2025	UK£2.5t	UK£2.0t	UK£133.0b	16.5x	18.6x	1.3x
Mon, 14 Apr 2025	UK£2.3t	UK£2.0t	UK£135.7b	14.7x	16.7x	1.1x
Wed, 12 Mar 2025	UK£2.4t	UK£2.0t	UK£137.7b	15.1x	17.7x	1.2x
Fri, 07 Feb 2025	UK£2.5t	UK£2.0t	UK£123.4b	16.1x	20.5x	1.2x
Sun, 05 Jan 2025	UK£2.4t	UK£2.1t	UK£123.5b	15.9x	19.6x	1.2x
Tue, 03 Dec 2024	UK£2.4t	UK£2.0t	UK£123.0b	16.3x	19.9x	1.2x
Thu, 31 Oct 2024	UK£2.4t	UK£2.0t	UK£120.7b	16.2x	20x	1.2x
Sat, 28 Sep 2024	UK£2.5t	UK£2.0t	UK£117.7b	16.9x	20.8x	1.2x
Mon, 26 Aug 2024	UK£2.5t	UK£2.0t	UK£119.5b	16.9x	20.5x	1.2x
Wed, 24 Jul 2024	UK£2.4t	UK£2.0t	UK£129.5b	16.7x	18.6x	1.2x
Fri, 21 Jun 2024	UK£2.4t	UK£2.0t	UK£131.9b	16.6x	18.5x	1.2x
Sun, 19 May 2024	UK£2.5t	UK£2.0t	UK£125.9b	17x	20x	1.2x
Tue, 16 Apr 2024	UK£2.4t	UK£2.1t	UK£148.3b	16.1x	16.2x	1.1x
Thu, 14 Mar 2024	UK£2.4t	UK£2.1t	UK£145.0b	16.2x	16.2x	1.1x
Sat, 10 Feb 2024	UK£2.3t	UK£2.0t	UK£144.7b	15.2x	15.6x	1.1x
Mon, 08 Jan 2024	UK£2.3t	UK£2.1t	UK£193.5b	15x	12.1x	1.1x
Wed, 06 Dec 2023	UK£2.3t	UK£2.1t	UK£193.6b	14.6x	11.7x	1.1x
Fri, 03 Nov 2023	UK£2.2t	UK£2.2t	UK£195.2b	13.8x	11.5x	1x
Sun, 01 Oct 2023	UK£2.3t	UK£2.2t	UK£186.2b	14.6x	12.6x	1.1x
Tue, 29 Aug 2023	UK£2.3t	UK£2.2t	UK£183.8b	14.5x	12.3x	1.1x
Thu, 27 Jul 2023	UK£2.4t	UK£2.2t	UK£205.9b	14.2x	11.7x	1.1x
Sat, 24 Jun 2023	UK£2.3t	UK£2.2t	UK£208.6b	14.1x	11.1x	1.1x


GB Market	2.65%
Materials	6.67%
Financials	5.97%
Real Estate	3.87%
Industrials	3.37%
Consumer Staples	2.07%
Telecom	1.89%
Consumer Discretionary	1.89%
Utilities	0.59%
Healthcare	-1.15%
Energy	-2.86%
Tech	-4.93%

Company	Last Price	7D	1Y	Valuation	Sector
HSBA HSBC Holdings	UK£14.10	7.5% +UK£16.8b	63.3%	PB1.6x	Financials
RR. Rolls-Royce Holdings	UK£13.93	13.7% +UK£13.9b	56.4%	PE19.7x	Industrials
RIO Rio Tinto Group	UK£78.92	5.7% +UK£6.9b	85.6%	PE17.3x	Materials
BARC Barclays	UK£4.87	8.7% +UK£5.2b	51.3%	PB0.9x	Financials
STAN Standard Chartered	UK£19.97	10.3% +UK£4.0b	72.8%	PB1.1x	Financials

Announcement • 20h

Rathbones Group plc and Rathbones Investment Management Limited Announce Board and Committee Changes

Rathbones Group Plc announced the appointment of Angela Seymour-Jackson and Kathryn Purves as Independent Non-Executive Directors of the Company with effect from October 1, 2026 and July 1, 2026 respectively, subject to regulatory approval. Angela Seymour-Jackson and Kathryn Purves will become members of the Risk, Audit, Remuneration and Nomination Committees following their appointment to the Board. These appointments followed a formal and rigorous selection process led by the Nomination Committee and formed part of the Board's ongoing succession planning as well as commitment to maintaining a broad range of skills, experience and independence. As previously announced in the Company's preliminary results on February 27, 2026, Sarah Gentleman, whose tenure on the Board has exceeded nine years, will step down from the Board and as Senior Independent Director during the second half of the year. As part of the Board's succession planning, it is intended that Angela Seymour-Jackson will succeed Sarah Gentleman as Senior Independent Director, subject to regulatory approval. Angela Seymour-Jackson has over 30 years of experience in retail financial services. She is currently Chair of PageGroup plc and a Non-Executive Director of Janus Henderson Group plc, Trustpilot Group plc and Future plc. Angela Seymour-Jackson has previously served as Chief Executive Officer of RAC Motoring Services and has held senior executive roles at Aegon UK, Aviva, Norwich Union Insurance, General Accident Insurance, and CGU plc. Kathryn Purves is a highly experienced financial services executive and board leader, with expertise across investment management, wealth advisory, private equity-backed businesses, and risk and governance. Kathryn Purves most recently served as Chief Executive Officer of Aztec Group, having previously been Chair and a Non-Executive Director. Prior to this, Kathryn Purves was Group Chief Executive Officer of IFG Group plc, has served as Chair of Risk Committee at Nucleus and ICG Plc. Kathryn Purves was also Chair of Redington and Saunderson House. Kathryn Purves has held senior executive roles, including Chief Risk Officer of Partnership Assurance Group, and investment roles at Phoenix Equity, Deutsche Bank, Partners and UBS Capital.

Announcement • Jun 13

Astrazeneca TRUQAP Combination Approves in the US as First and Only Targeted Treatment for PTEN-Deficient Metastatic Hormone-Sensitive Prostate Cancer

AstraZeneca’s TRUQAP (capivasertib) in combination with abiraterone and prednisone has been approved in the US as the first and only targeted treatment for adult patients with PTEN-deficient metastatic androgen pathway modulation-naïve or sensitive (mAPMN/S) prostate cancer, previously referred to as metastatic hormone-sensitive prostate cancer (mHSPC), as detected by a US Food and Drug Administration (FDA)-authorized test. The approval by the US FDA was based on positive results from the CAPItello-281 Phase III trial, presented at the 2025 European Society for Medical Oncology (ESMO) Congress and published in Annals of Oncology. Results from the primary analysis of the CAPItello-281 Phase III trial showed a statistically significant 19% reduction in the risk of radiographic disease progression or death and a clinically meaningful improvement in median radiographic progression-free survival (rPFS) of 7.5 months with TRUQAP in combination with abiraterone and androgen deprivation therapy (ADT) versus treatment with abiraterone and ADT with placebo (based on a hazard ratio [HR] of 0.81; 95% confidence interval [CI] 0.66–0.98; p=0.034). Median rPFS was 33.2 months for the TRUQAP combination versus 25.7 months for the comparator arm. While overall survival (OS) data were immature at the time of the primary analysis, results for OS numerically favored the TRUQAP combination versus the comparator arm. The trial will continue as planned to further assess OS as a key secondary endpoint. The safety profile of TRUQAP in combination with abiraterone and ADT in CAPItello-281 was broadly consistent with the known profile of each medicine. Grade 3 or higher adverse events occurred in 67% of patients treated with the TRUQAP combination, with rash (12.3%) and hyperglycemia (10.3%) the most frequently reported. Concurrently with this approval, the FDA also approved a companion diagnostic test to detect PTEN deficiency in tumors of patients with prostate adenocarcinoma. A regulatory application for the TRUQAP combination in this setting is under review in the EU based on the CAPItello-281 Phase III trial. TRUQAP is contraindicated in patients with severe hypersensitivity to TRUQAP or any of its components. TRUQAP can cause severe hyperglycemia, including diabetic ketoacidosis and fatal outcomes. In CAPItello-281, increased fasting glucose (FG) from baseline occurred in 69% of patients treated with TRUQAP, including 25% of patients with Grade 2 (FG >160 to 250 mg/dL), 12% with Grade 3 (FG >250 to 500 mg/dL), and 1.2% of patients with Grade 4 (FG >500 mg/dL) events. The median time to first occurrence of hyperglycemia was 71 days (range: 1 to 1454). Dose reduction for hyperglycemia was required in 8.7% of patients and permanent discontinuation was required in 2.4% of patients. Diabetic ketoacidosis occurred in 1.2% of patients. In the study, 41% (204/503) of patients who received TRUQAP had an anti-hyperglycemic medication regimen either initiated or changed, including treatment with insulin in 16% (81/503) of patients. The safety of TRUQAP has not been established in patients with Type 1 diabetes or Type 2 diabetes that is uncontrolled or requiring insulin at baseline as these patients were excluded from clinical studies. Before initiating treatment with TRUQAP, test fasting glucose levels (FPG or FBG), HbA1C levels, and optimize fasting glucose. After initiating treatment with TRUQAP, monitor or self-monitor FG levels on Day 3 or 4 of the dosing week during weeks 1, 2, 4, 6, and 8; then monthly while on treatment with TRUQAP; and as clinically indicated. Monitor HbA1C levels every 3 months during treatment with TRUQAP and as clinically indicated. Patients with a history of well-controlled Type 2 diabetes mellitus may require intensified anti-hyperglycemic treatment and close monitoring of FG levels. For patients who experience hyperglycemia during treatment with TRUQAP, monitor FG at least twice weekly, on days on and off TRUQAP, until FG decreases to baseline levels. During treatment with anti-diabetic medications, monitor FG at least once a week for 2 months, followed by once every 2 weeks, or as clinically indicated. Consider consultation with a healthcare practitioner with expertise in the treatment of hyperglycemia and initiation of FG monitoring at home for patients who have risk factors for hyperglycemia or who experience hyperglycemia. Advise patients on the signs and symptoms of hyperglycemia and counsel patients on lifestyle changes. Withhold TRUQAP immediately when ketoacidosis is suspected. If ketoacidosis is confirmed, permanently discontinue TRUQAP. Withhold TRUQAP in clinical situations known to increase the risk of severe hyperglycemia or ketoacidosis (eg, suspected serious infection or acute illness). Based on the severity of hyperglycemia, withhold, reduce dose, or permanently discontinue TRUQAP. TRUQAP can cause severe diarrhea associated with dehydration. In CAPItello-281, diarrhea of any grade occurred in 264 (52%) patients. Grade 3 occurred in 31 (6%) patients and Grade 4 occurred in 1 (0.2%) patient. The median time to first occurrence was 12 days (range: 3 to 48). In the study, dose reductions were required in 26 (5%) patients and 6 (1.2%) patients discontinued TRUQAP due to diarrhea. In the 264 patients with diarrhea, anti-diarrheal medication was required in 64% (170/264) of patients to manage diarrhea symptoms. Monitor patients for signs and symptoms of diarrhea. Advise patients to increase oral fluids and start anti-diarrheal treatment at the first sign of diarrhea while taking TRUQAP. Withhold, reduce dose, or permanently discontinue TRUQAP based on severity. TRUQAP can cause cutaneous adverse reactions, which can be severe, including erythema multiforme (EM), palmar-plantar erythrodysesthesia (PPE), and drug reaction with eosinophilia and systemic symptoms (DRESS). In CAPItello-281, cutaneous adverse reactions occurred in 53% of patients. Grade 3 cutaneous adverse reactions occurred in 84 (17%) patients and Grade 4 occurred in 1 (0.2%) patients. The median time to onset of rash was 13 days (range: 11 to 63 days). In the study, dose reduction was required in 58 (12%) patients and 38 (8%) patients discontinued TRUQAP due to rash. Among the 265 patients with cutaneous adverse reactions, 80% (212/265) required treatment and 91% (242/265) recovered in the study. Of these, 54% (115/212) were treated with topical corticosteroids and 25% (54/212) with systemic corticosteroids. Monitor patients for signs and symptoms of cutaneous adverse reactions. Early consultation with a dermatologist is recommended. Withhold, reduce dose, or permanently discontinue TRUQAP based on severity. Based on findings from animals and mechanism of action, TRUQAP can cause fetal harm when administered to a pregnant woman.

U.K. (FTSE) Market Analysis & Valuation

Market Valuation and Performance

Sector Trends

Top Stock Gainers and Losers

Market Insights

Software stocks just gave investors a masterclass

Latest News

Allianz Reportedly Most Likely Buyer of HSBC Holdings' Singapore Insurance Unit

Rathbones Group plc and Rathbones Investment Management Limited Announce Board and Committee Changes

Barclays Stock in Focus as Bank Acquires GoHenry to Expand Youth and Family Banking

Rio Tinto Pilbara Ore Passes Key Emissions Reduction Steelmaking Trials in China

Rolls-Royce to Benefit From £24b UK Japan Tech and Defence Investment Deal

BP Restructures Leadership and Sells Gulf Stakes While Whiting Labor Dispute Continues

Final dividend increased to UK£0.15

Astrazeneca TRUQAP Combination Approves in the US as First and Only Targeted Treatment for PTEN-Deficient Metastatic Hormone-Sensitive Prostate Cancer

Experian Launches Experian Verify for Research Verification

RELX Launches £200 Million Buyback as AI Opportunities and Risks Come Into Focus

LLOY: Motor Finance Uncertainty And Buybacks Will Still Limit Future Upside

Standard Chartered plc Announces Appointment of Tanate Phutrakul as Independent Non-Executive Director and to Audit and Board Risk Committees, Effective July 1, 2026

Shell Advances $3 Billion Buy-Back and Supports $12.6 Billion Raízen Restructuring

ANTO: Copper And Geopolitical Risks Will Restrain Future Share Performance

BA.: Expanding Space And Missile Defense Exposure Should Support Earnings Repricing

AAL: Copper And Iron Ore Downside Risks Will Drive Cautious Outlook